Core Viewpoint - Rosen Law Firm is reminding purchasers of Tronox Holdings plc common stock of the upcoming lead plaintiff deadline for a class action lawsuit, indicating potential compensation for investors who bought shares during the specified period [1][2]. Group 1: Class Action Details - The class action pertains to investors who purchased Tronox common stock between February 12, 2025, and July 30, 2025, with a lead plaintiff deadline set for November 3, 2025 [1][2]. - Investors can join the class action without incurring out-of-pocket fees through a contingency fee arrangement [1]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success and recognition in this field [3]. - The firm has achieved significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [3]. Group 3: Case Allegations - The lawsuit alleges that Tronox's management made misleading statements regarding the company's growth and performance in its pigment and zircon commercial division, which ultimately led to a failure in meeting revenue projections [4]. - It is claimed that while positive statements were made to investors, there were material adverse facts being concealed about the company's ability to forecast demand and manage costs, resulting in investor damages when the truth was revealed [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, of the upcoming lead plaintiff deadline on November 7, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Savara securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 7, 2025 [2] - The lawsuit claims that Savara's defendants made false or misleading statements regarding the approval process of the MOLBREEVI Biologics License Application (BLA) [4] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3] - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking No. 1 for settlements in 2017 [3] Group 3: Case Specifics - The lawsuit alleges that the defendants failed to disclose critical information about the MOLBREEVI BLA, which affected the likelihood of FDA approval and the company's capital needs [4] - The claims suggest that the public statements made by the defendants were materially false and misleading, leading to investor damages when the true information became public [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fortinet, Inc. common stock during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the Fortinet common stock purchases is from November 8, 2024, to August 6, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A lead plaintiff must move the Court by November 21, 2025, to represent other class members in the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3] Group 3: Case Allegations - The lawsuit alleges that Fortinet made materially false and misleading statements regarding the business impact of a "record" round of FortiGate unit upgrades, claiming it would generate $400 million to $450 million in product revenue in 2025 and 2026 [4] - Defendants misrepresented the sustainability of the refresh cycle, which was said to consist of old products that were only a "small percentage" of the company's business [5] - The lawsuit claims that when the true details of the refresh cycle were revealed, investors suffered damages due to the misleading information provided by Fortinet [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of aTyr Pharma, Inc. during the specified class period of the upcoming lead plaintiff deadline on December 8, 2025 [1]. Group 1: Class Action Details - Investors who bought aTyr Pharma common stock between January 16, 2025, and September 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lead plaintiff must file a motion with the court by December 8, 2025, to represent other class members in the litigation [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The complaint alleges that defendants made misleading statements regarding the efficacy of Efzofitimod, particularly its ability to allow patients to taper steroid usage completely, leading to investor damages when the truth was revealed [5].

Core Points - Rosen Law Firm is reminding purchasers of Marex Group plc securities from May 16, 2024, to August 5, 2025, about the December 8, 2025, lead plaintiff deadline [1] - Investors who purchased Marex securities during the specified period may be entitled to compensation through a contingency fee arrangement [1] Class Action Details - A class action lawsuit has been filed against Marex Group plc, with allegations of materially false and misleading statements regarding the company's financial practices [4] - Specific claims include Marex selling over-the-counter financial instruments to itself, inconsistencies in financial statements, and misleading positive statements about the company's business and prospects [4] Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience [3] - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Jasper Therapeutics, Inc. securities during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1]. Group 1: Class Action Details - Investors who bought Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by November 18, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false or misleading statements regarding its manufacturing controls and compliance with regulations, which could negatively impact the prospects of its products, including briquilimab [5]. - The failure to ensure proper manufacturing processes increased the risk of confounding study results, potentially leading to disruptive cost-reduction measures and overstated business prospects [5]. - The lawsuit claims that when the true details became public, investors suffered damages due to the misleading statements made by the defendants [5].

Core Viewpoint - A class action lawsuit has been filed against Avantor, Inc. on behalf of shareholders who purchased common stock during the specified class period from March 5, 2024, to October 28, 2025 [1] Company Summary - Avantor, Inc. is a provider of scientific products and services catering to various industries [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, of the upcoming lead plaintiff deadline on November 7, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Savara securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the November 7, 2025 deadline [2] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [5] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3] - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly in securities class action settlements since 2013 [3] Group 3: Case Allegations - The lawsuit alleges that Savara's defendants made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [4] - It is claimed that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital, and that public statements made by the defendants were materially false and misleading [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Coty, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Financial Performance - Coty disclosed its financial results for the full fiscal year of 2025 and its fourth quarter in a Current Report on Form 8-K filed on August 20, 2025 [3]. - The Chief Financial Officer of Coty attributed sluggish sales to several factors, including value-seeking behavior, innovation fatigue among consumers, and changes in anti-theft and immigration policies [3]. Group 2: Stock Market Reaction - Following the news of Coty's financial performance, the company's stock price fell by $1.05 per share, representing a decline of 21.6%, closing at $3.81 per share on August 21, 2025 [4]. Group 3: Legal Action and Investor Rights - Investors who purchased Coty securities may be entitled to compensation through a class action lawsuit being prepared by Rosen Law Firm, which operates on a contingency fee basis [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [5].

Core Points - Rosen Law Firm is reminding investors who purchased Marex Group plc securities between May 16, 2024, and August 5, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Company Details - The lawsuit alleges that Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements between subsidiaries [4] - The misleading statements led to investors suffering damages when the true details were revealed [4] Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions, as many firms may not have the necessary experience [3] - Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [3]